MetaCap

China Pharma (CPHI) vs Pasithea Therapeutics (KTTA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Pasithea Therapeutics (KTTA) has outperformed China Pharma (CPHI) over the past year, gaining 63.9% versus a loss of 72.6%. Over five years, KTTA leads with a -99.4% price change compared with -99.8% for CPHI. China Pharma is the larger company by market cap ($18.9 million vs $17.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CPHI-72.60%KTTA+63.94%
+430%+167%-97%
Nov 21, 20251 yearNov 20, 2026
CPHI-99.85%KTTA-98.99%
+78%-15%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CPHI versus KTTA key metrics
MetricCPHIKTTA
Share price$0.4384$0.4787
Market cap$18.86M$17.59M
1-day change-13.00%-0.48%
YTD return-63.77%-62.89%
1-year return-72.60%+63.94%
5-year return-99.84%-99.40%
EPS (TTM)$-0.42$-1.38
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$4.14M—
Revenue growth (YoY)-8.49%—
Net income (latest FY)$-3.19M$-20.43M
Gross margin-3.18%—
Operating margin-78.16%—
Net margin-76.91%—
52-week high$19.19$2.06
52-week low$0.38$0.32
Distance from 52-week high-97.72%-76.76%
Analyst consensus—none
Avg. price target upside—+526.70%
Average volume1.60M705.64K
Shares outstanding43.02M36.75M
Employees2155
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KTTA has outperformed CPHI by 136.5 percentage points over the past year.

About China Pharma

CPHI stock →

China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China.

Health Care · Biotechnology: Pharmaceutical Preparations · 215 employees

About Pasithea Therapeutics

KTTA stock →

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

CPHI vs KTTA FAQ

Which is bigger, China Pharma or Pasithea Therapeutics?

China Pharma (CPHI) is larger, with a market capitalization of $18.86M compared with $17.59M for Pasithea Therapeutics (KTTA).

Which stock has performed better over the past year, CPHI or KTTA?

KTTA returned +63.94% over the past 12 months, compared with -72.60% for CPHI (price return, excluding dividends). Past performance does not predict future results.

Are China Pharma and Pasithea Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons